Genetic instability and cellular proliferation have been associated with Aurora-kinase expression in several cancer entities, including multiple myeloma. Therefore, the expression of Aurora-A, -B and -C was determined by Affymetrix DNA-microarrays in 784 samples including two independent sets of 233 and 345 CD138-purified myeloma-cells from previously untreated myeloma-patients.
Introduction
Multiple myeloma is an incurable malignant disease of clonal plasma cells which accumulate in the bone marrow causing clinical signs and symptoms related to the displacement of normal hematopoiesis, formation of osteolytic bone lesions, and production of monoclonal protein 1 .
Multiple myeloma cells (MMC) at the time of diagnosis are characterized by a low proliferation rate that increases in relapse 2 . Presence of proliferation correlates with adverse prognosis 3;4 . At the same time, myeloma cells harbor a high median number of chromosomal aberrations 5;6 , often associated with genetic instability 6 . Proliferation 7 and chromosomal instability 8 in turn are associated with the expression of Aurora-kinases. In several cancer entities, Aurora-kinases have been implicated in tumor formation and progression [9] [10] [11] [12] [13] [14] .
Aurora-kinases represent a family of conserved mitotic regulators comprising three closely related members, i.e. Aurora-A, -B and -C 9 . Aurora-C expression is restricted to germ cells, where it regulates spermatogenesis 15 . Aurora-A associates with the centrosome and spindle microtubules being required for centrosome separation and spindle assembly 7 . Aurora-B is a member of the chromosomal passenger complex, as such sequentially recruited to centromeres, spindle midzone and midbody as mitosis progresses 16 , and required for chromosome biorientation, the spindle assembly checkpoint, and cytokinesis 7 . Inhibition of Aurora-A and -B exhibits distinct phenotypic features: loss of Aurora-A activity induces a centrosome separation defect and a monopolar spindle phenotype 17;18 ; inhibition of Aurora-B generates polyploidy through defects in cytokinesis, which ultimately leads to a loss in cell viability [19] [20] [21] [22] . Aurora-A and -B expression has been detected by quantitative real-time PCR (qRT-PCR) in myeloma cell lines 23;24 and small series of myeloma patients 23;24 . Aurora-kinase inhibitors like VX680 have been shown to abrogate proliferation and induce apoptosis in human myeloma cells lines and primary myeloma cells [23] [24] [25] .
We assess here the expression of Aurora-A, -B, and -C in 784 Affymetrix gene expression profiles of malignant plasma cells from previously untreated myeloma patients compared to normal bone marrow plasma cells (BMPC), their non-malignant proliferating precursors (polyclonal plasmablastic cells, PPC), and human myeloma cell lines (HMCL). We find that in our data set 24 % of previously untreated myeloma patients express Aurora-A. We show myeloma cells expressing Aurora-A kinase to have a higher proliferation-rate, whereas the number of chromosomal aberrations (aneuploidy) is not higher compared to myeloma cells with absent Aurora-A expression. The same holds true for subclonal aberrations (i.e. genetic instability), which are less frequent in myeloma cell-samples expressing Aurora-A. Aurora-A kinase expression in turn is significantly associated with an inferior event-free (EFS) and overall survival (OAS) in two independent cohorts of a total of 513 myeloma-patients treated with high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
Aurora-kinase inhibitors (including VX680 tested here) are very active on human myeloma cell lines and primary myeloma cells and represent a promising weapon in the therapeutic arsenal against multiple myeloma. Gene expression profiling allows an assessment of Aurora-kinase expression and thus in turn a tailoring of treatment to patients expressing these kinases. 29 . Survival data were validated by an independent cohort of 345 patients treated within the total therapy 2 protocol 30 . For clinical parameters, see Supplementary Table S1 .
Materials and Methods

Patients and healthy donors
Samples
For an overview, see Supplementary Table S2 . Plasma cells from the bone marrow were purified using CD138-microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) and purity was assessed by flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany). 37 were generated and analyzed as previously published.
Chemicals
The 4,6 diaminopyrimidine VX680 (Cyclopropanecarboxylicarid{4[4(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulfanyl]-phenyl}-amide; ACC corporation, San Diego, CA, USA) was dissolved in dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) and stored at a final concentration of 10 mM at -80 °C.
Interphase-FISH (iFISH)
Interphase-FISH-analysis was performed on CD138-purified plasma cells as described 5 
Gene expression profiling (GEP)
RNA extraction was performed using the RNeasy kit (Qiagen, Hilden, Germany), the SV-total RNA extraction kit (Promega, Mannheim, Germany) and Trizol (Invitrogen, Karlsruhe, Germany).
Labeled cRNA was generated using the small sample labeling protocol vII (Affymetrix, Santa Clara, CA, USA), and hybridized to U133 A+B GeneChip microarray (Affymetrix) for training, 
Survival of primary myeloma cells
Primary MMC cultured together with their bone marrow microenvironment (negative fraction of plasma cell purification) of 5 newly-diagnosed patients were exposed to concentrations of 100, 20, 4, 0.8, 0.16, 0.032 µM VX680. Cell viability was measured by CD138-FITC (IQ products, Groningen, Netherlands, clone B-A38) / PI (Pharmingen, Heidelberg, Germany) staining after 6 days of culture and referred to the medium and DMSO-control, respectively 44 . One µl of PI with a concentration of 50 µg/ml was used.
Apoptosis induction
XG-1 and XG-10 were cultured in 24-well-plates at 10 
Statistical analysis
Gene expression data were gcrma-normalized 45 .
To assess presence or absence of gene expression independently of Affymetrix-mismatch-probesets, the "Presence-Absence calls with Negative Probesets (PANP)" algorithm 46 was used. Differential gene expression was assessed using empirical Bayes statistics in linear models for microarray data 47 . Chng et al. 49 . For the calculation on the Arkansas-group, our 7 BMPC samples were normalized together with the 345 MMC-samples.
The gene expression based proliferation index is calculated as described in Supplementary Text S1.
In all statistical tests, an effect was considered as statistically significant if the P-value of its corresponding statistical test was not greater than 5 %. All statistical computations were performed using R 50 version 2.7.0 and Bioconductor 51 , version 2.2.
Results
Expression of Aurora-A, -B and -C
First, we assessed expression (Table 1 ,2) and differential expression (Supplementary Table S3A,B) of 
Validation of gene expression by qRT-PCR, western blotting and flow cytometry
To validate Aurora-kinase expression detected by gene expression profiling, we performed qRT-PCR, western blotting and flow-cytometric staining. Aurora-A expression in terms of "presence" or "absence" (C t -value (exemplary data shown in Figure 2C ).
Association of Aurora-kinase expression with proliferation and chromosomal aberrations
To investigate the biological impact of Aurora-kinase expression, we assessed the association with proliferation, chromosomal aberrations and presence of subclonal aberrations as detected by iFISH, and a published centrosome-index 49 . Figure S1 ).
Prognostic value of Aurora-kinase-expression
Next, we investigated whether the presence of Aurora-kinase expression has a prognostic impact in newly-diagnosed myeloma patients treated with HDT and ASCT. In a Cox-model tested with the international staging system (ISS), presence of Aurora-A expression appears as independent prognostic factor for EFS in our data (Aurora A-expression (P=.003), ISS (P=.009)), and the Arkansas-data (Aurora-A expression (P<.001), ISS (P<.001)). For OAS, Aurora-A expression marginally fails independence (P=.08), ISS (P=.009)) in our data-set, but is significantly independent in the Arkansas-data (Aurora-A expression (P<.001), ISS (P<.001)).
In a Cox-model tested with serum-β2-microglobulin (B2M) as continuous variable, presence of Aurora-A expression appears as independent prognostic factor for EFS in our data (Aurora-A expression (P=.002), B2M (P=.006)), and the Arkansas-data (Aurora-A expression (P<.001), B2M
(P<.001)), and OAS (Aurora-A expression (P=.06), B2M (P<.001)), and the Arkansas-data (Aurora-A expression (P<.001), B2M (P<.001)).
Activity of VX680 on myeloma cell lines and primary myeloma cells
Given the expression and prognostic value of Aurora-kinases, we tested the activity of the panAurora-kinase inhibitor VX680 that has previously shown activity on a small series of human . Alternate explanations are a more advanced (relapsed) patient population, or a contamination by other cell types, as in these series, purity of CD138-sorted plasma cells was only assessed by morphology, and expression of Aurora-A and -B could be detected in almost all our bone marrow samples (Table 1 ,2).
The lower frequency of Aurora-B compared to Aurora-A expression in the same sample as detected by GEP seems likewise to be related to the detection-threshold: (i) In normal plasma cells, the expression levels of Aurora-A and -B are of the same height (Supplementary Table S3A 
Biological implications
Aurora-kinases have been associated with proliferation 7 and genetic instability 8 in different cancer entities [9] [10] [11] [12] [13] [14] , including multiple myeloma 25 . Taken together, it is unlikely that Aurora-kinase expression in CD138-purified myeloma cells drives genetic instability in myeloma, but is, as a high labeling index and the presence of chromosomal aberrations associated with disease "progression", rather a sign of proliferative, "advanced" myeloma cells.
Aurora-A and
Prognostic value of Aurora-kinase expression
Presence of Aurora-A expression in myeloma cells is an adverse prognostic factor in terms of EFS and OAS in our data (n=168) and the Arkansas-group (n=345, Figure 3) , as is the expression-height of Aurora-A as single continuous variable.
In a Cox-model tested with either ISS or B2M
(as continuous variable), presence of Aurora-A expression appears as independent prognostic factor for EFS and OAS. Of note, Aurora-A (STK6) is also one of the genes within the gene expression based high-risk score for myeloma 54 . Aurora-A kinase expression in our data set correlates with the gene expression based centrosome index that has likewise shown prognostic significance on the Arkansas-dataset 49 (Supplementary Figure S1) . Thus, direct assessment of Aurora-A kinase expression allows identifying a poor-risk patient population independent of B2M or ISS.
Inhibition of proliferation of HMCL and primary MMC by Aurora-kinase inhibitors
Proliferation of all tested 20 myeloma cell lines is significantly inhibited by VX680 with an IC50 ranging from 0.003 to 2.715 µM ( Figure 4A2 ). The observed minimal IC50 is in the range of data from Tyler et al. 19 who have shown an inhibition of in vitro kinase activity by VX680 in terms of phosphorylation of histone-H3 by Aurora-A, -B, and -C (with IC50-values of 36, 18, and 25 nM, respectively); Aurora-A and -B kinase activity was completely abrogated at 1 µM 19 . VX680
induced a marked delay in mitosis, presumably due to Aurora-A dependent effects on spindle bipolarity, but did override a mitotic arrest imposed by several experimental agents, indicating an effect on the spindle assembly checkpoint, likely through Aurora-B inhibition 19 . Our data are in agreement with VX680 having been shown to induce a dose-dependent inhibition of proliferation on myeloma cell lines 25 . Inhibition of proliferation by VX680 was accompanied in our hands by apoptosis induction in myeloma cell lines and primary myeloma cell-samples in agreement with findings from Shi et al. 25 . Driven by the published observation that forced over-expression of Aurora-A reduces 25 , and downregulation by siRNA increases 23 the susceptibility of myeloma cell lines towards Aurora-kinase inhibitors, we investigated whether the IC50 in 12 myeloma cell lines tested might correlate with the expression level of Aurora-A. However, in our hands, it did not. The same observation was made in terms of expression of HMMR, for which a forced up-regulation was described to increase, and a down-regulation to decrease the sensitivity of the respective myeloma cell line 25 , but does not in our data. This might be explained by a plethora of growth and survivalfactors differentially expressed between HMCL causing a high inter-cell-line variance in terms of sensitivity against VX680 ( Figure 4A2 ). Thus, only if Aurora-A or HMMR-expression is the single parameter varied (e.g. by siRNA) within one cell line, differences in the sensitivity of the respective HMCL might be seen.
Implications for myeloma treatment
The presence of multiple chromosomal aberrations in multiple myeloma suggests that, during the evolution of myeloma, a disruption of cell cycle checkpoints has occurred. This would normally arrest cells at the G1/S and G2/M transitions or at mitosis when DNA-damage or spindle abnormalities have occurred, thus allowing for potential damage-repair 25 . Alternatively or in addition, these checkpoints might be "overruled" by intrinsic aberrant or increased expression of D-type cyclins and myeloma growth and survival factors ("strained" checkpoints). In both cases, myeloma cells might be particularly susceptible to the induction of apoptotic death in mitosis (the so-called mitotic catastrophe 55 ) when further assaults on the mitotic machinery are induced.
Experimental evidence for the latter is given by the fact that VX680 inhibits proliferation of both, CD3/CD28-or phytohaemagglutinin-stimulated peripheral blood lymphocytes and myeloma cell lines, but induces apoptosis only in human myeloma cell lines 25 . Thus, Aurora-kinase inhibitors are indicated in multiple myeloma not because myeloma cells show a genetic instability, but because Aurora-kinase inhibitors target and inhibit the proliferation of myeloma cells. They might do this especially efficient because they (additionally) induce apoptosis in the presence of strained or deranged cell-cycle checkpoints present in primary myeloma cells and human myeloma cell lines.
Conclusion
Aurora-A is expressed at varying frequencies in CD138-purified myeloma cells of newly-diagnosed patients. Its expression significantly interrelates with proliferation, but not with a higher number of chromosomal aberrations (aneuploidy) or subclonal aberrations (genetic instability). Using gene expression profiling, Aurora-kinase inhibitors as promising therapeutic option for newly-diagnosed patients can be tailoredly given to patients expressing Aurora-A with adverse prognosis. Figure 4 . Table 2 . Presence of expression of Aurora-kinase A, -B and -C. 
